Free Trial

Elevance Health (ELV) Financials

Elevance Health logo
$377.85 +1.87 (+0.50%)
Closing price 05/28/2025 03:59 PM Eastern
Extended Trading
$376.60 -1.25 (-0.33%)
As of 05/28/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Elevance Health

Annual Income Statements for Elevance Health

This table shows Elevance Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders
5,980 5,987 5,894 6,158 4,572 4,807 3,750 3,843 2,470 2,560
Consolidated Net Income / (Loss)
5,971 5,991 5,888 6,149 4,572 4,807 3,750 3,843 2,470 2,560
Net Income / (Loss) Continuing Operations
5,971 5,991 5,888 6,149 4,572 4,807 3,750 3,843 2,470 2,560
Total Pre-Tax Income
7,904 7,715 7,600 7,995 6,238 5,985 5,068 3,964 4,555 4,631
Total Operating Income
8,888 8,745 8,451 8,793 7,058 6,733 5,832 4,985 5,278 5,275
Total Gross Profit
29,493 29,717 26,918 25,173 24,869 20,435 20,210 17,804 18,029 18,040
Total Revenue
176,810 171,340 156,595 138,639 121,867 104,213 92,105 90,040 84,863 79,157
Operating Revenue
177,255 171,340 156,595 138,639 115,552 104,213 86,185 90,040 84,863 79,157
Other Revenue
-445 - - - 6,315 - 5,920 - - -
Total Cost of Revenue
147,317 141,623 129,677 113,466 96,998 83,778 71,895 72,236 66,834 61,117
Operating Cost of Revenue
147,317 141,623 129,677 113,466 96,998 83,778 71,895 72,236 66,834 61,117
Total Operating Expenses
20,605 20,972 18,467 16,380 17,811 13,702 14,378 12,819 12,751 12,765
Selling, General & Admin Expense
20,025 20,087 17,700 15,918 17,450 13,364 14,020 12,650 12,559 12,535
Amortization Expense
580 885 767 441 361 338 358 169 192 230
Total Other Income / (Expense), net
-984 -1,030 -851 -798 -820 -748 -764 -1,021 -723 -644
Interest Expense
1,185 1,030 851 798 820 748 764 1,021 723 644
Other Income / (Expense), net
201 0.00 0.00 - - - - - - -
Income Tax Expense
1,933 1,724 1,712 1,846 1,666 1,178 1,318 121 2,085 2,071
Net Income / (Loss) Attributable to Noncontrolling Interest
-9.00 4.00 -6.00 -9.00 0.00 0.00 - - - -
Basic Earnings per Share
$25.81 $25.38 $24.56 $25.26 $18.23 $18.81 $14.53 $14.70 $9.39 $9.73
Weighted Average Basic Shares Outstanding
227.35M 232.67M 237.46M 482.61M 489.81M 252.33M 258.10M 261.50M 262.90M 263M
Diluted Earnings per Share
$25.68 $25.22 $24.28 $24.95 $17.98 $18.47 $14.19 $14.35 $9.21 $9.38
Weighted Average Diluted Shares Outstanding
227.35M 232.67M 237.46M 482.61M 489.81M 252.33M 258.10M 261.50M 262.90M 263M
Weighted Average Basic & Diluted Shares Outstanding
227.35M 232.67M 237.46M 482.61M 489.81M 252.33M 258.10M 261.50M 262.90M 263M
Cash Dividends to Common per Share
$6.52 $5.92 $5.12 $4.52 $3.80 $3.20 $3.00 $2.70 $2.60 $2.50

Quarterly Income Statements for Elevance Health

This table shows Elevance Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
2,183 418 1,016 2,300 2,246 856 1,289 1,853 1,989 865 1,603
Consolidated Net Income / (Loss)
2,184 413 1,008 2,301 2,249 831 1,300 1,856 2,004 877 1,598
Net Income / (Loss) Continuing Operations
2,184 413 1,008 2,301 2,249 831 1,300 1,856 2,004 877 1,598
Total Pre-Tax Income
2,797 606 1,373 2,986 2,939 1,001 1,654 2,441 2,619 1,045 2,127
Total Operating Income
3,141 946 1,712 3,026 3,204 1,260 1,913 2,702 2,870 1,274 2,340
Total Gross Profit
8,596 16,265 1,834 3,188 8,206 11,294 7,595 2,923 7,905 6,088 7,081
Total Revenue
48,891 45,442 45,145 43,646 42,577 42,647 42,849 43,672 42,172 39,929 39,939
Operating Revenue
48,891 45,516 45,270 43,731 42,738 42,413 42,849 43,793 42,285 39,929 39,939
Total Cost of Revenue
40,295 29,177 43,311 40,458 34,371 31,353 35,254 40,749 34,267 33,841 32,858
Operating Cost of Revenue
40,295 29,177 43,311 40,458 34,371 31,353 35,254 40,749 34,267 33,841 32,858
Total Operating Expenses
5,455 15,319 122 162 5,002 10,034 5,682 221 5,035 4,814 4,741
Selling, General & Admin Expense
5,300 - - - 4,886 - 5,470 - 4,800 4,567 4,516
Amortization Expense
155 180 122 162 116 217 212 221 235 247 225
Total Other Income / (Expense), net
-344 -340 -339 -40 -265 -259 -259 -261 -251 -229 -213
Interest Expense
344 340 300 280 265 259 259 261 251 229 213
Income Tax Expense
613 193 365 685 690 170 354 585 615 168 529
Net Income / (Loss) Attributable to Noncontrolling Interest
1.00 -5.00 -8.00 1.00 3.00 -25 11 3.00 15 12 -5.00
Basic Earnings per Share
$9.64 $1.87 $4.38 $9.91 $9.65 $3.70 $5.48 $7.83 $8.37 $3.66 $6.69
Weighted Average Basic Shares Outstanding
225.93M 227.35M 231.92M 231.89M 232.42M 232.67M 234.96M 235.65M 237.06M 237.46M 238.83M
Diluted Earnings per Share
$9.61 $1.88 $4.36 $9.85 $9.59 $3.68 $5.45 $7.79 $8.30 $3.61 $6.62
Weighted Average Diluted Shares Outstanding
225.93M 227.35M 231.92M 231.89M 232.42M 232.67M 234.96M 235.65M 237.06M 237.46M 238.83M
Weighted Average Basic & Diluted Shares Outstanding
225.93M 227.35M 231.92M 231.89M 232.42M 232.67M 234.96M 235.65M 237.06M 237.46M 238.83M
Cash Dividends to Common per Share
$1.71 - $1.63 $1.63 $1.63 - $1.48 $1.48 $1.48 - $1.28

Annual Cash Flow Statements for Elevance Health

This table details how cash moves in and out of Elevance Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents
1,828 -861 2,507 -861 804 1,003 325 -466 1,962 -38
Net Cash From Operating Activities
5,808 8,061 8,399 8,364 10,688 6,061 3,827 4,185 3,270 4,212
Net Cash From Continuing Operating Activities
5,808 8,061 8,399 8,364 10,688 6,128 3,827 4,185 3,270 4,212
Net Income / (Loss) Continuing Operations
5,971 5,991 5,888 6,149 4,572 4,807 3,750 3,843 2,470 2,560
Consolidated Net Income / (Loss)
5,971 5,991 5,888 6,149 4,572 4,807 3,750 3,843 2,470 2,560
Depreciation Expense
1,393 1,745 1,675 1,302 1,154 1,133 1,132 111 104 106
Non-Cash Adjustments To Reconcile Net Income
537 1,462 528 -552 248 201 432 235 97 21
Changes in Operating Assets and Liabilities, net
-2,093 -1,137 308 1,465 4,714 -13 -1,487 -784 -209 723
Net Cash From Investing Activities
-5,167 -5,572 -4,560 -9,638 -7,324 -2,792 -1,259 -5,082 -514 -1,152
Net Cash From Continuing Investing Activities
-5,167 -5,572 -4,560 -9,638 -7,324 -2,792 -1,259 -5,082 -514 -1,152
Purchase of Property, Plant & Equipment
-1,256 -1,296 -1,152 -1,087 -1,021 -1,077 -1,208 -791 -584 -638
Acquisitions
-4,809 -1,552 -649 -3,476 -1,976 0.00 -1,760 -2,080 0.00 -639
Purchase of Investments
-17,913 -16,158 -25,247 -19,625 -20,341 -22,700 -9,820 -16,375 -11,845 -11,681
Divestitures
363 0.00 0.00 - - - - - - -
Sale and/or Maturity of Investments
18,572 13,536 22,608 14,613 16,059 21,035 11,600 14,152 11,918 11,780
Other Investing Activities, net
-124 -102 -120 -63 -45 -50 -71 12 -3.00 -8.20
Net Cash From Financing Activities
1,193 -3,349 -1,318 423 -2,567 -2,266 -2,241 427 -799 -3,093
Net Cash From Continuing Financing Activities
1,193 -3,349 -1,318 423 -2,567 -2,266 -2,241 427 -799 -3,093
Repayment of Debt
-1,783 -2,167 -3,533 -2,091 -3,750 -9,455 -11,227 -7,815 -2,553 -4,635
Repurchase of Common Equity
-2,900 -2,676 -2,316 -1,900 -2,700 -1,701 -1,685 -1,998 0.00 -1,516
Payment of Dividends
-1,508 -1,395 -1,229 -1,104 -954 -818 -776 -705 -684 -657
Issuance of Debt
7,985 2,799 4,436 4,837 3,454 9,859 9,955 11,468 2,400 3,987
Issuance of Common Equity
221 152 182 - - - 1,250 0.00 0.00 -
Other Financing Activities, net
-822 -62 1,142 681 1,383 -151 242 -523 38 -272
Effect of Exchange Rate Changes
-6.00 -1.00 -14 -10 7.00 0.00 -2.00 4.00 5.00 -5.30

Quarterly Cash Flow Statements for Elevance Health

This table details how cash moves in and out of Elevance Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
-788 468 1,368 292 -300 -4,393 928 -151 2,755 -1,485 2,416
Net Cash From Operating Activities
1,017 706 2,677 447 1,978 -2,971 2,613 1,950 6,469 -1,518 4,924
Net Cash From Continuing Operating Activities
1,017 706 2,677 447 1,978 -2,971 2,613 1,950 6,469 -1,518 4,924
Net Income / (Loss) Continuing Operations
2,184 413 1,008 2,301 2,249 831 1,300 1,856 2,004 877 1,598
Consolidated Net Income / (Loss)
2,184 413 1,008 2,301 2,249 831 1,300 1,856 2,004 877 1,598
Depreciation Expense
373 398 329 335 331 424 426 433 462 473 451
Non-Cash Adjustments To Reconcile Net Income
419 29 322 -64 250 371 645 242 204 202 80
Changes in Operating Assets and Liabilities, net
-1,959 -134 1,018 -2,125 -852 -4,597 242 -581 3,799 -3,070 2,795
Net Cash From Investing Activities
103 -1,638 -401 -818 -2,310 -1,029 -687 -672 -3,184 289 -1,247
Net Cash From Continuing Investing Activities
103 -1,638 -401 -818 -2,310 -1,029 -687 -672 -3,184 289 -1,247
Purchase of Property, Plant & Equipment
-196 -322 -332 -323 -279 -326 -319 -350 -301 -298 -305
Acquisitions
4.00 -3,685 - -4.00 -1,120 18 81 -13 -1,638 -26 -14
Purchase of Investments
-4,254 -3,047 -4,510 -4,041 -6,315 8,124 -6,779 -10,264 -7,239 -4,958 -6,416
Sale and/or Maturity of Investments
4,574 5,480 4,472 3,187 5,433 -8,825 6,366 9,973 6,022 5,600 5,521
Other Investing Activities, net
-25 -28 -31 -36 -29 -20 -36 -18 -28 -29 -33
Net Cash From Financing Activities
-1,909 1,408 -915 668 32 -394 -994 -1,430 -531 -258 -1,255
Net Cash From Continuing Financing Activities
-1,909 1,408 -915 668 32 -394 -994 -1,430 -531 -258 -1,255
Repayment of Debt
-1,379 -917 -874 4.00 4.00 1.00 -265 3.00 -1,906 -1,192 -33
Repurchase of Common Equity
-880 -1,811 -60 -463 -566 -928 -480 -646 -622 -568 -579
Payment of Dividends
-386 -373 -378 -378 -379 -346 -348 -350 -351 -305 -306
Issuance of Debt
0.00 5,195 210 1,230 1,350 225 - -325 2,899 1,410 201
Other Financing Activities, net
736 -907 187 275 -377 502 99 -112 -551 215 -538
Effect of Exchange Rate Changes
1.00 -8.00 7.00 -5.00 0.00 1.00 -4.00 1.00 1.00 2.00 -6.00

Annual Balance Sheets for Elevance Health

This table presents Elevance Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets
116,889 108,928 102,755 97,456 86,615 77,453 71,571 70,540 65,083 61,718
Total Current Assets
58,942 60,029 55,617 51,122 45,751 39,033 34,321 36,263 34,315 30,862
Cash & Equivalents
8,288 6,526 7,387 4,880 5,741 4,937 3,934 3,609 4,075 2,114
Short-Term Investments
26,393 29,843 26,905 28,148 24,992 20,685 18,368 21,156 18,812 18,552
Accounts Receivable
11,060 9,963 8,961 7,759 5,679 5,377 4,836 4,847 8,397 7,024
Other Current Assets
13,201 13,697 12,364 10,335 9,339 8,034 7,173 6,309 2,862 2,856
Plant, Property, & Equipment, net
4,652 4,359 4,316 3,919 3,483 3,133 2,735 2,175 1,978 2,020
Total Noncurrent Assets
53,295 44,540 42,822 42,415 37,381 35,287 34,515 32,102 28,790 28,836
Long-Term Investments
10,784 6,983 6,437 5,857 4,847 4,763 4,213 3,905 2,796 2,630
Goodwill
28,277 25,317 24,383 24,228 21,691 20,500 20,504 19,231 17,561 17,562
Intangible Assets
12,094 10,273 10,315 10,615 9,405 8,674 9,007 8,368 7,965 8,158
Other Noncurrent Operating Assets
2,140 1,967 1,687 1,715 1,438 1,350 791 598 468 485
Total Liabilities & Shareholders' Equity
116,889 108,928 102,755 97,456 86,615 77,453 71,571 70,540 65,083 61,718
Total Liabilities
75,463 69,523 66,425 61,293 53,416 45,725 43,030 44,037 39,983 38,674
Total Current Liabilities
40,581 41,791 39,696 34,885 29,453 23,532 21,965 23,356 21,294 19,093
Short-Term Debt
2,014 1,874 1,765 1,874 700 2,298 1,994 2,550 1,368 540
Accounts Payable
6,927 6,910 5,607 4,970 16,852 4,198 12,413 13,016 11,908 10,889
Other Current Liabilities
31,487 33,007 32,324 28,041 11,901 17,036 6,879 7,266 6,868 6,291
Other Current Nonoperating Liabilities
153 0.00 - - - - - - - -
Total Noncurrent Liabilities
34,882 27,732 26,729 26,408 23,963 22,193 21,065 20,681 18,688 19,581
Long-Term Debt
29,218 23,246 22,349 21,157 19,335 17,787 17,217 17,382 14,359 15,325
Noncurrent Deferred & Payable Income Tax Liabilities
2,148 1,970 2,015 2,815 2,019 2,227 1,960 1,727 2,780 2,631
Other Noncurrent Operating Liabilities
3,516 2,516 2,365 2,436 2,609 2,179 1,888 1,572 1,550 1,626
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
41,426 39,405 36,330 36,163 33,199 31,728 28,541 26,503 25,100 23,044
Total Preferred & Common Equity
41,315 39,306 36,243 36,095 33,199 31,728 28,541 26,503 25,100 23,044
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
41,315 39,306 36,243 36,095 33,199 31,728 28,541 26,503 25,100 23,044
Common Stock
8,913 8,870 9,086 9,150 9,247 9,451 9,539 8,550 8,808 8,558
Retained Earnings
33,549 31,749 29,647 27,142 23,802 22,573 19,988 18,054 16,561 14,779
Accumulated Other Comprehensive Income / (Loss)
-1,147 -1,313 -2,490 -197 150 -296 -986 -101 -268 -293
Noncontrolling Interest
111 99 87 68 0.00 - - - - -

Quarterly Balance Sheets for Elevance Health

This table presents Elevance Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Total Assets
119,717 116,889 116,533 112,988 111,894 108,928 110,478 109,168 109,040 102,755 103,026
Total Current Assets
61,121 58,942 62,846 62,274 60,948 60,029 61,185 59,743 59,823 55,617 55,603
Cash & Equivalents
7,500 8,288 7,866 6,497 6,226 6,526 10,919 9,991 10,142 7,387 8,872
Short-Term Investments
26,152 26,393 30,067 29,494 30,041 29,843 27,976 28,293 28,028 26,905 27,029
Accounts Receivable
11,822 11,060 11,190 11,178 9,362 9,963 9,049 9,092 8,464 8,961 7,524
Other Current Assets
15,647 13,201 13,723 15,105 15,319 13,697 13,241 12,367 13,189 12,364 12,178
Plant, Property, & Equipment, net
4,617 4,652 4,505 4,450 4,451 4,359 4,248 4,547 4,418 4,316 4,197
Total Noncurrent Assets
53,979 53,295 49,182 46,264 46,495 44,540 45,045 44,878 44,799 42,822 43,226
Long-Term Investments
11,227 10,784 10,287 7,659 7,593 6,983 6,934 6,768 6,754 6,437 6,138
Goodwill
28,420 28,277 25,967 25,962 25,947 25,317 25,291 25,274 25,273 24,383 24,381
Intangible Assets
11,940 12,094 10,325 10,447 10,710 10,273 10,491 10,703 10,915 10,315 10,536
Other Noncurrent Operating Assets
2,392 2,140 2,603 2,196 2,245 1,967 2,329 2,133 1,857 1,687 2,171
Total Liabilities & Shareholders' Equity
119,717 116,889 116,533 112,988 111,894 108,928 110,478 109,168 109,040 102,755 103,026
Total Liabilities
77,097 75,463 72,654 70,691 71,184 69,523 71,939 70,856 71,580 66,425 66,983
Total Current Liabilities
42,698 40,581 42,033 41,813 44,334 41,791 43,337 41,571 41,889 39,696 41,287
Short-Term Debt
1,893 2,014 2,460 3,125 4,475 1,874 799 265 265 1,765 2,514
Accounts Payable
7,131 6,927 6,255 5,760 5,658 6,910 5,983 5,033 4,873 5,607 20,205
Other Current Liabilities
33,674 31,487 33,155 32,763 34,201 33,007 36,555 36,273 36,751 32,324 18,568
Other Current Nonoperating Liabilities
0.00 153 163 165 - 0.00 - - - - -
Total Noncurrent Liabilities
34,399 34,882 30,621 28,878 26,850 27,732 28,602 29,285 29,691 26,729 25,696
Long-Term Debt
28,110 29,218 24,688 24,561 21,976 23,246 24,045 24,859 25,201 22,349 21,258
Noncurrent Deferred & Payable Income Tax Liabilities
2,121 2,148 2,092 2,037 2,201 1,970 1,779 1,852 2,029 2,015 1,825
Other Noncurrent Operating Liabilities
4,168 3,516 3,841 2,280 2,673 2,516 2,778 2,574 2,461 2,365 2,613
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
42,620 41,426 43,879 42,297 40,710 39,405 38,539 38,312 37,460 36,330 36,043
Total Preferred & Common Equity
42,503 41,315 43,775 42,191 40,608 39,306 38,423 38,205 37,356 36,243 35,991
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
42,503 41,315 43,775 42,191 40,608 39,306 38,423 38,205 37,356 36,243 35,991
Common Stock
8,868 8,913 9,107 9,003 8,885 8,870 8,832 8,763 8,699 9,086 9,171
Retained Earnings
34,546 33,549 35,157 34,575 33,088 31,749 32,103 31,608 30,707 29,647 29,604
Accumulated Other Comprehensive Income / (Loss)
-911 -1,147 -489 -1,387 -1,365 -1,313 -2,512 -2,166 -2,050 -2,490 -2,784
Noncontrolling Interest
117 111 104 106 102 99 116 107 104 87 52

Annual Metrics And Ratios for Elevance Health

This table displays calculated financial ratios and metrics derived from Elevance Health's official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics
- - - - - - - - - -
Revenue Growth
3.19% 9.42% 12.95% 13.76% 16.94% 13.15% 2.29% 6.10% 7.21% 7.15%
EBITDA Growth
-0.08% 3.59% 0.31% 22.93% 4.40% 12.95% 18.52% -5.07% 0.12% 4.77%
EBIT Growth
3.93% 3.48% -3.89% 24.58% 4.83% 15.45% 16.99% -5.55% 0.06% 4.45%
NOPAT Growth
-1.13% 3.72% -3.19% 30.73% -4.34% 25.32% -10.71% 68.86% -1.84% -1.48%
Net Income Growth
-0.33% 1.75% -4.24% 34.49% -4.89% 28.19% -2.42% 55.59% -3.52% -0.38%
EPS Growth
1.82% 3.87% -2.69% 38.77% -2.65% 30.16% -1.12% 55.81% -1.81% 4.34%
Operating Cash Flow Growth
-27.95% -4.02% 0.42% -21.74% 76.34% 58.37% -8.55% 27.98% -22.36% 25.01%
Free Cash Flow Firm Growth
-89.85% -25.32% 73.85% -54.09% 71.50% 518.61% -61.87% -33.61% 25.29% -25.53%
Invested Capital Growth
29.16% 7.40% -2.92% 15.04% -17.61% 0.90% 19.54% 17.31% -3.01% 1.67%
Revenue Q/Q Growth
1.61% 1.61% 2.18% 3.55% 3.76% 4.03% 0.76% 1.09% 1.83% 1.54%
EBITDA Q/Q Growth
-1.31% -0.60% -2.21% 10.16% -5.05% -2.89% 3.18% -4.39% 4.92% -7.08%
EBIT Q/Q Growth
-1.23% -0.16% -3.89% 10.85% -6.38% 9.07% 2.72% -5.05% 5.79% -8.57%
NOPAT Q/Q Growth
-5.22% -0.36% -3.47% 10.20% -6.87% 10.68% -22.43% 38.90% 7.36% -9.91%
Net Income Q/Q Growth
-6.54% -0.76% -4.04% 11.37% -7.73% 11.87% -17.71% 28.93% 8.22% -11.29%
EPS Q/Q Growth
-6.55% 0.28% -4.07% 11.63% -7.18% 12.48% -17.74% 29.75% 7.47% -10.33%
Operating Cash Flow Q/Q Growth
172.55% -15.27% -27.53% -20.38% 30.31% 16.63% 85.51% -27.38% -19.03% 21.31%
Free Cash Flow Firm Q/Q Growth
-67.55% -24.22% -11.38% -44.15% 10.64% 11.12% 119.62% -62.71% -1.08% 1.30%
Invested Capital Q/Q Growth
19.05% 20.62% 10.91% 6.60% -12.91% -6.03% -6.08% 39.34% -0.37% -1.82%
Profitability Metrics
- - - - - - - - - -
Gross Margin
16.68% 17.34% 17.19% 18.16% 20.41% 19.61% 21.94% 19.77% 21.24% 22.79%
EBITDA Margin
5.93% 6.12% 6.47% 7.28% 6.74% 7.55% 7.56% 6.53% 7.29% 7.81%
Operating Margin
5.03% 5.10% 5.40% 6.34% 5.79% 6.46% 6.33% 5.54% 6.22% 6.66%
EBIT Margin
5.14% 5.10% 5.40% 6.34% 5.79% 6.46% 6.33% 5.54% 6.22% 6.66%
Profit (Net Income) Margin
3.38% 3.50% 3.76% 4.44% 3.75% 4.61% 4.07% 4.27% 2.91% 3.23%
Tax Burden Percent
75.54% 77.65% 77.47% 76.91% 73.29% 80.32% 73.99% 96.95% 54.23% 55.28%
Interest Burden Percent
86.96% 88.22% 89.93% 90.92% 88.38% 88.89% 86.90% 79.52% 86.30% 87.80%
Effective Tax Rate
24.46% 22.35% 22.53% 23.09% 26.71% 19.68% 26.01% 3.05% 45.77% 44.72%
Return on Invested Capital (ROIC)
27.68% 33.22% 32.72% 35.63% 26.47% 25.35% 22.13% 29.37% 18.61% 18.83%
ROIC Less NNEP Spread (ROIC-NNEP)
32.28% 37.81% 36.78% 39.54% 31.12% 32.18% 29.18% 39.96% 23.12% 23.19%
Return on Net Nonoperating Assets (RNNOA)
-12.90% -17.40% -16.47% -17.90% -12.39% -9.40% -8.50% -14.48% -8.35% -8.01%
Return on Equity (ROE)
14.77% 15.82% 16.24% 17.73% 14.08% 15.95% 13.63% 14.89% 10.26% 10.83%
Cash Return on Invested Capital (CROIC)
2.23% 26.09% 35.69% 21.64% 45.79% 24.45% 4.32% 13.44% 21.66% 17.17%
Operating Return on Assets (OROA)
8.05% 8.26% 8.44% 9.55% 8.60% 9.04% 8.21% 7.35% 8.32% 8.55%
Return on Assets (ROA)
5.29% 5.66% 5.88% 6.68% 5.57% 6.45% 5.28% 5.67% 3.90% 4.15%
Return on Common Equity (ROCE)
14.74% 15.78% 16.21% 17.71% 14.08% 15.95% 13.63% 14.89% 10.26% 10.83%
Return on Equity Simple (ROE_SIMPLE)
14.45% 15.24% 16.25% 17.04% 13.77% 15.15% 13.14% 14.50% 9.84% 11.11%
Net Operating Profit after Tax (NOPAT)
6,714 6,791 6,547 6,763 5,173 5,408 4,315 4,833 2,862 2,916
NOPAT Margin
3.80% 3.96% 4.18% 4.88% 4.24% 5.19% 4.69% 5.37% 3.37% 3.68%
Net Nonoperating Expense Percent (NNEP)
-4.60% -4.59% -4.06% -3.91% -4.65% -6.83% -7.05% -10.59% -4.51% -4.36%
Return On Investment Capital (ROIC_SIMPLE)
9.24% 10.52% 10.83% - - - - - - -
Cost of Revenue to Revenue
83.32% 82.66% 82.81% 81.84% 79.59% 80.39% 78.06% 80.23% 78.76% 77.21%
SG&A Expenses to Revenue
11.33% 11.72% 11.30% 11.48% 14.32% 12.82% 15.22% 14.05% 14.80% 15.84%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
11.65% 12.24% 11.79% 11.81% 14.62% 13.15% 15.61% 14.24% 15.03% 16.13%
Earnings before Interest and Taxes (EBIT)
9,089 8,745 8,451 8,793 7,058 6,733 5,832 4,985 5,278 5,275
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
10,482 10,490 10,126 10,095 8,212 7,866 6,964 5,876 6,190 6,183
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
2.07 2.78 3.29 3.05 2.32 2.30 2.24 2.03 1.38 1.42
Price to Tangible Book Value (P/TBV)
90.63 29.42 77.25 87.80 36.65 28.56 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.48 0.64 0.76 0.79 0.63 0.70 0.69 0.60 0.41 0.41
Price to Earnings (P/E)
14.31 18.26 20.25 17.85 16.86 15.17 17.06 13.99 14.07 12.79
Dividend Yield
1.77% 1.27% 1.02% 1.00% 1.23% 1.11% 1.21% 1.29% 1.97% 1.99%
Earnings Yield
6.99% 5.48% 4.94% 5.60% 5.93% 6.59% 5.86% 7.15% 7.11% 7.82%
Enterprise Value to Invested Capital (EV/IC)
2.61 4.31 5.22 4.64 3.49 2.92 2.67 2.53 1.64 1.62
Enterprise Value to Revenue (EV/Rev)
0.40 0.53 0.66 0.68 0.51 0.60 0.62 0.50 0.29 0.32
Enterprise Value to EBITDA (EV/EBITDA)
6.82 8.69 10.15 9.33 7.49 7.96 8.14 7.66 4.01 4.10
Enterprise Value to EBIT (EV/EBIT)
7.86 10.43 12.17 10.71 8.72 9.30 9.71 9.03 4.70 4.80
Enterprise Value to NOPAT (EV/NOPAT)
10.64 13.43 15.70 13.92 11.90 11.58 13.13 9.32 8.66 8.68
Enterprise Value to Operating Cash Flow (EV/OCF)
12.30 11.31 12.24 11.25 5.76 10.34 14.80 10.76 7.58 6.01
Enterprise Value to Free Cash Flow (EV/FCFF)
131.96 17.10 14.40 22.92 6.88 12.01 67.18 20.36 7.44 9.52
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.75 0.64 0.66 0.64 0.60 0.63 0.67 0.75 0.63 0.69
Long-Term Debt to Equity
0.71 0.59 0.62 0.59 0.58 0.56 0.60 0.66 0.57 0.67
Financial Leverage
-0.40 -0.46 -0.45 -0.45 -0.40 -0.29 -0.29 -0.36 -0.36 -0.35
Leverage Ratio
2.79 2.80 2.76 2.65 2.53 2.47 2.58 2.63 2.63 2.61
Compound Leverage Factor
2.43 2.47 2.48 2.41 2.23 2.20 2.24 2.09 2.27 2.29
Debt to Total Capital
42.98% 38.93% 39.89% 38.91% 37.64% 38.76% 40.23% 42.92% 38.52% 40.77%
Short-Term Debt to Total Capital
2.77% 2.90% 2.92% 3.17% 1.31% 4.44% 4.18% 5.49% 3.35% 1.39%
Long-Term Debt to Total Capital
40.21% 36.03% 36.97% 35.74% 36.32% 34.33% 36.06% 37.43% 35.17% 39.39%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.15% 0.15% 0.14% 0.11% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
56.86% 60.92% 59.96% 60.98% 62.36% 61.24% 59.77% 57.08% 61.48% 59.23%
Debt to EBITDA
2.98 2.39 2.38 2.28 2.44 2.55 2.76 3.39 2.54 2.57
Net Debt to EBITDA
-1.36 -1.74 -1.64 -1.57 -1.89 -1.31 -1.05 -1.49 -1.61 -1.20
Long-Term Debt to EBITDA
2.79 2.22 2.21 2.10 2.35 2.26 2.47 2.96 2.32 2.48
Debt to NOPAT
4.65 3.70 3.68 3.41 3.87 3.71 4.45 4.12 5.50 5.44
Net Debt to NOPAT
-2.12 -2.68 -2.54 -2.34 -3.01 -1.90 -1.69 -1.81 -3.48 -2.55
Long-Term Debt to NOPAT
4.35 3.42 3.41 3.13 3.74 3.29 3.99 3.60 5.02 5.26
Altman Z-Score
3.04 3.39 3.46 3.39 3.15 3.24 3.05 2.82 2.69 2.64
Noncontrolling Interest Sharing Ratio
0.26% 0.25% 0.21% 0.10% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
1.45 1.44 1.40 1.47 1.55 1.66 1.56 1.55 1.61 1.62
Quick Ratio
1.13 1.11 1.09 1.17 1.24 1.32 1.24 1.27 1.47 1.45
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
541 5,333 7,141 4,108 8,947 5,217 843 2,212 3,331 2,659
Operating Cash Flow to CapEx
462.42% 621.99% 729.08% 769.46% 1,046.82% 562.77% 316.80% 529.08% 559.93% 698.61%
Free Cash Flow to Firm to Interest Expense
0.46 5.18 8.39 5.15 10.91 6.97 1.10 2.17 4.61 4.13
Operating Cash Flow to Interest Expense
4.90 7.83 9.87 10.48 13.03 8.10 5.01 4.10 4.52 6.54
Operating Cash Flow Less CapEx to Interest Expense
3.84 6.57 8.52 9.12 11.79 6.66 3.43 3.32 3.72 5.61
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
1.57 1.62 1.56 1.51 1.49 1.40 1.30 1.33 1.34 1.28
Accounts Receivable Turnover
16.82 18.11 18.73 20.63 22.05 20.41 19.02 13.60 11.01 11.34
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
39.24 39.50 38.03 37.46 36.84 35.52 37.52 43.36 42.46 39.94
Accounts Payable Turnover
21.29 22.63 24.52 10.40 9.22 10.09 5.65 5.80 5.86 5.71
Days Sales Outstanding (DSO)
21.70 20.16 19.49 17.69 16.56 17.89 19.19 26.84 33.16 32.20
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
17.14 16.13 14.89 35.10 39.61 36.19 64.55 62.97 62.25 63.91
Cash Conversion Cycle (CCC)
4.56 4.03 4.60 -17.41 -23.05 -18.30 -45.36 -36.12 -29.08 -31.71
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
27,346 21,173 19,715 20,309 17,654 21,428 21,237 17,765 15,144 15,613
Invested Capital Turnover
7.29 8.38 7.83 7.30 6.24 4.89 4.72 5.47 5.52 5.11
Increase / (Decrease) in Invested Capital
6,173 1,458 -594 2,655 -3,774 191 3,472 2,621 -469 257
Enterprise Value (EV)
71,434 91,195 102,823 94,136 61,540 62,643 56,653 45,018 24,793 25,321
Market Capitalization
85,556 109,328 119,351 109,922 77,085 72,943 63,957 53,756 34,749 32,752
Book Value per Share
$178.14 $167.29 $151.75 $148.71 $133.49 $125.13 $110.35 $103.22 $95.28 $88.27
Tangible Book Value per Share
$4.07 $15.82 $6.47 $5.16 $8.46 $10.07 ($3.75) ($4.27) ($1.62) ($10.25)
Total Capital
72,658 64,525 60,444 59,194 53,234 51,813 47,752 46,435 40,827 38,909
Total Debt
31,232 25,120 24,114 23,031 20,035 20,085 19,211 19,932 15,727 15,865
Total Long-Term Debt
29,218 23,246 22,349 21,157 19,335 17,787 17,217 17,382 14,359 15,325
Net Debt
-14,233 -18,232 -16,615 -15,854 -15,545 -10,300 -7,304 -8,738 -9,957 -7,431
Capital Expenditures (CapEx)
1,256 1,296 1,152 1,087 1,021 1,077 1,208 791 584 603
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-14,306 -16,257 -16,606 -14,917 -13,735 -7,823 -7,952 -9,308 -8,498 -8,356
Debt-free Net Working Capital (DFNWC)
20,375 20,112 17,686 18,111 16,998 17,799 14,350 15,457 14,389 12,310
Net Working Capital (NWC)
18,361 18,238 15,921 16,237 16,298 15,501 12,356 12,907 13,021 11,770
Net Nonoperating Expense (NNE)
743 800 659 614 601 601 565 990 392 356
Net Nonoperating Obligations (NNO)
-14,080 -18,232 -16,615 -15,854 -15,545 -10,300 -7,304 -8,738 -9,957 -7,431
Total Depreciation and Amortization (D&A)
1,393 1,745 1,675 1,302 1,154 1,133 1,132 891 912 908
Debt-free, Cash-free Net Working Capital to Revenue
-8.09% -9.49% -10.60% -10.76% -11.27% -7.51% -8.63% -10.34% -10.01% -10.56%
Debt-free Net Working Capital to Revenue
11.52% 11.74% 11.29% 13.06% 13.95% 17.08% 15.58% 17.17% 16.96% 15.55%
Net Working Capital to Revenue
10.38% 10.64% 10.17% 11.71% 13.37% 14.87% 13.42% 14.33% 15.34% 14.87%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
$25.81 $25.38 $25.10 $25.04 $18.23 $18.81 $14.53 $14.70 $9.39 $9.73
Adjusted Weighted Average Basic Shares Outstanding
227.35M 232.67M 237.46M 482.61M 489.81M 252.33M 257.01M 255.72M 264.38M 261.35M
Adjusted Diluted Earnings per Share
$25.68 $25.22 $24.81 $24.73 $17.98 $18.47 $14.19 $14.35 $9.21 $9.38
Adjusted Weighted Average Diluted Shares Outstanding
227.35M 232.67M 237.46M 482.61M 489.81M 252.33M 257.01M 255.72M 264.38M 261.35M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
227.35M 232.67M 237.46M 482.61M 489.81M 252.33M 257.01M 255.72M 264.38M 261.35M
Normalized Net Operating Profit after Tax (NOPAT)
6,714 6,791 6,547 6,779 5,173 5,408 4,315 4,833 2,862 2,916
Normalized NOPAT Margin
3.80% 3.96% 4.18% 4.89% 4.24% 5.19% 4.69% 5.37% 3.37% 3.68%
Pre Tax Income Margin
4.47% 4.50% 4.85% 5.77% 5.12% 5.74% 5.50% 4.40% 5.37% 5.85%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
7.67 8.49 9.93 11.02 8.61 9.00 7.63 4.88 7.30 8.19
NOPAT to Interest Expense
5.67 6.59 7.69 8.47 6.31 7.23 5.65 4.73 3.96 4.53
EBIT Less CapEx to Interest Expense
6.61 7.23 8.58 9.66 7.36 7.56 6.05 4.11 6.49 7.26
NOPAT Less CapEx to Interest Expense
4.61 5.33 6.34 7.11 5.06 5.79 4.07 3.96 3.15 3.59
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
25.26% 23.28% 20.87% 17.95% 20.87% 17.02% 20.69% 18.35% 27.69% 25.65%
Augmented Payout Ratio
73.82% 67.95% 60.21% 48.85% 79.92% 52.40% 65.63% 70.34% 27.69% 84.86%

Quarterly Metrics And Ratios for Elevance Health

This table displays calculated financial ratios and metrics derived from Elevance Health's official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - - -
Revenue Growth
14.83% 6.55% 5.36% -0.06% 0.96% 6.81% 7.29% 13.05% 10.70% 9.15% 11.49%
EBITDA Growth
-0.59% -20.19% -14.41% 14.86% 6.09% -3.61% -16.19% 15.13% 16.30% -13.73% 9.54%
EBIT Growth
-1.97% -24.92% -12.55% 20.87% 11.64% -1.10% -18.25% 15.97% 14.48% -23.48% 6.51%
NOPAT Growth
0.03% -38.36% -16.41% 13.50% 11.64% -2.17% -14.47% 14.51% 13.55% -19.94% 6.34%
Net Income Growth
-2.89% -50.30% -22.46% 23.98% 12.23% -5.25% -18.65% 13.59% 12.65% -25.61% 6.39%
EPS Growth
0.21% -48.91% -20.00% 26.44% 15.54% 1.94% -17.67% 15.75% 13.39% -25.72% 7.99%
Operating Cash Flow Growth
-48.58% 123.76% 2.45% -77.08% -69.42% -95.72% -46.93% -20.47% 154.58% -190.79% 96.65%
Free Cash Flow Firm Growth
30.09% -1,241.86% -341.03% -273.56% -181.89% -124.77% -43.13% 60.93% 226.90% 226.04% 5.67%
Invested Capital Growth
19.07% 29.16% 30.85% 44.14% 29.44% 7.40% -1.25% -6.50% -6.64% -2.92% -6.70%
Revenue Q/Q Growth
7.59% 0.66% 3.43% 2.51% -0.16% -0.47% -1.88% 3.56% 5.62% -0.03% 3.38%
EBITDA Q/Q Growth
161.46% -32.87% -44.40% 1.87% 109.92% -28.00% -25.39% -5.91% 90.73% -37.41% 2.50%
EBIT Q/Q Growth
232.03% -43.45% -48.78% 1.94% 154.29% -34.13% -29.20% -5.85% 125.27% -45.56% 0.43%
NOPAT Q/Q Growth
280.42% -48.71% -46.10% -4.89% 134.39% -30.43% -26.81% -6.45% 105.40% -39.18% -2.01%
Net Income Q/Q Growth
428.81% -59.03% -56.19% 2.31% 170.64% -36.08% -29.96% -7.39% 128.51% -45.12% -2.20%
EPS Q/Q Growth
411.17% -56.88% -55.74% 2.71% 160.60% -32.48% -30.04% -6.14% 129.92% -45.47% -1.63%
Operating Cash Flow Q/Q Growth
44.05% -73.63% 498.88% -77.40% 166.58% -213.70% 34.00% -69.86% 526.15% -130.83% 100.82%
Free Cash Flow Firm Q/Q Growth
64.00% -32.92% 28.07% -103.08% -591.10% -123.88% -48.20% -4.19% 109.06% -45.18% 46.56%
Invested Capital Q/Q Growth
1.46% 19.05% -13.31% 13.72% 10.05% 20.62% -4.51% 2.12% -8.69% 10.91% -9.59%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
17.58% 35.79% 4.06% 7.30% 19.27% 26.48% 17.73% 6.69% 18.74% 15.25% 17.73%
EBITDA Margin
7.19% 2.96% 4.43% 8.25% 8.30% 3.95% 5.46% 7.18% 7.90% 4.38% 6.99%
Operating Margin
6.42% 2.08% 3.79% 6.93% 7.53% 2.95% 4.46% 6.19% 6.81% 3.19% 5.86%
EBIT Margin
6.42% 2.08% 3.71% 7.48% 7.53% 2.95% 4.46% 6.19% 6.81% 3.19% 5.86%
Profit (Net Income) Margin
4.47% 0.91% 2.23% 5.27% 5.28% 1.95% 3.03% 4.25% 4.75% 2.20% 4.00%
Tax Burden Percent
78.08% 68.15% 73.42% 77.06% 76.52% 83.02% 78.60% 76.03% 76.52% 83.92% 75.13%
Interest Burden Percent
89.05% 64.06% 82.07% 91.43% 91.73% 79.44% 86.46% 90.34% 91.25% 82.03% 90.90%
Effective Tax Rate
21.92% 31.85% 26.58% 22.94% 23.48% 16.98% 21.40% 23.97% 23.48% 16.08% 24.87%
Return on Invested Capital (ROIC)
35.99% 10.34% 23.91% 40.88% 47.89% 20.56% 33.50% 40.98% 44.88% 20.95% 36.63%
ROIC Less NNEP Spread (ROIC-NNEP)
37.66% 11.77% 25.10% 41.05% 48.99% 21.79% 34.53% 42.08% 45.94% 22.14% 37.55%
Return on Net Nonoperating Assets (RNNOA)
-14.59% -4.71% -12.76% -18.20% -23.10% -10.03% -18.17% -20.50% -22.63% -9.92% -18.30%
Return on Equity (ROE)
21.40% 5.63% 11.15% 22.69% 24.78% 10.53% 15.32% 20.48% 22.25% 11.04% 18.33%
Cash Return on Invested Capital (CROIC)
8.90% 2.23% 8.23% -3.53% 8.46% 26.09% 39.84% 43.88% 43.40% 35.69% 43.76%
Operating Return on Assets (OROA)
10.16% 3.26% 5.68% 11.57% 11.70% 4.78% 7.05% 9.76% 10.44% 4.99% 8.93%
Return on Assets (ROA)
7.06% 1.42% 3.42% 8.15% 8.21% 3.15% 4.79% 6.71% 7.29% 3.44% 6.10%
Return on Common Equity (ROCE)
21.35% 5.62% 11.12% 22.63% 24.72% 10.50% 15.29% 20.44% 22.20% 11.01% 18.30%
Return on Equity Simple (ROE_SIMPLE)
13.90% 0.00% 14.60% 15.84% 15.36% 0.00% 15.71% 16.58% 16.36% 0.00% 17.05%
Net Operating Profit after Tax (NOPAT)
2,453 645 1,257 2,332 2,452 1,046 1,504 2,054 2,196 1,069 1,758
NOPAT Margin
5.02% 1.42% 2.78% 5.34% 5.76% 2.45% 3.51% 4.70% 5.21% 2.68% 4.40%
Net Nonoperating Expense Percent (NNEP)
-1.66% -1.43% -1.19% -0.17% -1.10% -1.23% -1.04% -1.10% -1.06% -1.18% -0.91%
Return On Investment Capital (ROIC_SIMPLE)
3.38% 0.89% - - - 1.62% - - - 1.77% -
Cost of Revenue to Revenue
82.42% 64.21% 95.94% 92.70% 80.73% 73.52% 82.28% 93.31% 81.26% 84.75% 82.27%
SG&A Expenses to Revenue
10.84% 0.00% 0.00% 0.00% 11.48% 0.00% 12.77% 0.00% 11.38% 11.44% 11.31%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
11.16% 33.71% 0.27% 0.37% 11.75% 23.53% 13.26% 0.51% 11.94% 12.06% 11.87%
Earnings before Interest and Taxes (EBIT)
3,141 946 1,673 3,266 3,204 1,260 1,913 2,702 2,870 1,274 2,340
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
3,514 1,344 2,002 3,601 3,535 1,684 2,339 3,135 3,332 1,747 2,791
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.33 2.07 2.75 2.98 3.00 2.78 2.64 2.72 2.89 3.29 2.98
Price to Tangible Book Value (P/TBV)
46.15 90.63 16.11 21.78 30.84 29.42 38.37 46.68 92.29 77.25 99.97
Price to Revenue (P/Rev)
0.54 0.48 0.69 0.73 0.71 0.64 0.60 0.63 0.67 0.76 0.70
Price to Earnings (P/E)
16.71 14.31 18.79 18.82 19.51 18.26 16.90 16.48 17.69 20.25 17.41
Dividend Yield
1.52% 1.77% 1.23% 1.15% 1.17% 1.27% 1.33% 1.26% 1.17% 1.02% 1.11%
Earnings Yield
5.98% 6.99% 5.32% 5.31% 5.12% 5.48% 5.92% 6.07% 5.65% 4.94% 5.74%
Enterprise Value to Invested Capital (EV/IC)
3.03 2.61 4.34 4.15 4.49 4.31 4.58 4.58 4.91 5.22 5.02
Enterprise Value to Revenue (EV/Rev)
0.46 0.40 0.57 0.64 0.61 0.53 0.48 0.51 0.55 0.66 0.58
Enterprise Value to EBITDA (EV/EBITDA)
8.20 6.82 9.38 10.08 9.78 8.69 7.63 7.65 8.35 10.15 8.61
Enterprise Value to EBIT (EV/EBIT)
9.53 7.86 10.83 11.71 11.51 10.43 9.19 9.16 10.03 12.17 10.14
Enterprise Value to NOPAT (EV/NOPAT)
12.53 10.64 14.06 15.03 14.83 13.43 11.81 11.91 12.99 15.70 13.15
Enterprise Value to Operating Cash Flow (EV/OCF)
17.36 12.30 46.74 53.26 29.28 11.31 8.46 7.12 7.17 12.24 7.69
Enterprise Value to Free Cash Flow (EV/FCFF)
37.03 131.96 59.71 0.00 59.82 17.10 11.44 10.09 10.93 14.40 11.06
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.70 0.75 0.62 0.65 0.65 0.64 0.64 0.66 0.68 0.66 0.66
Long-Term Debt to Equity
0.66 0.71 0.56 0.58 0.54 0.59 0.62 0.65 0.67 0.62 0.59
Financial Leverage
-0.39 -0.40 -0.51 -0.44 -0.47 -0.46 -0.53 -0.49 -0.49 -0.45 -0.49
Leverage Ratio
2.78 2.79 2.75 2.76 2.83 2.80 2.86 2.83 2.85 2.76 2.80
Compound Leverage Factor
2.48 1.79 2.26 2.52 2.59 2.22 2.48 2.56 2.60 2.27 2.54
Debt to Total Capital
41.31% 42.98% 38.22% 39.56% 39.38% 38.93% 39.20% 39.61% 40.47% 39.89% 39.74%
Short-Term Debt to Total Capital
2.61% 2.77% 3.46% 4.47% 6.66% 2.90% 1.26% 0.42% 0.42% 2.92% 4.20%
Long-Term Debt to Total Capital
38.71% 40.21% 34.76% 35.10% 32.72% 36.03% 37.94% 39.19% 40.05% 36.97% 35.54%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.16% 0.15% 0.15% 0.15% 0.15% 0.15% 0.18% 0.17% 0.17% 0.14% 0.09%
Common Equity to Total Capital
58.53% 56.86% 61.63% 60.29% 60.46% 60.92% 60.62% 60.23% 59.37% 59.96% 60.17%
Debt to EBITDA
2.92 2.98 2.56 2.54 2.47 2.39 2.35 2.28 2.40 2.38 2.30
Net Debt to EBITDA
-1.45 -1.36 -1.98 -1.46 -1.63 -1.74 -1.99 -1.81 -1.84 -1.64 -1.76
Long-Term Debt to EBITDA
2.74 2.79 2.32 2.25 2.06 2.22 2.28 2.26 2.38 2.21 2.05
Debt to NOPAT
4.47 4.65 3.83 3.78 3.75 3.70 3.65 3.55 3.74 3.68 3.51
Net Debt to NOPAT
-2.22 -2.12 -2.97 -2.18 -2.47 -2.68 -3.08 -2.82 -2.86 -2.54 -2.69
Long-Term Debt to NOPAT
4.19 4.35 3.49 3.35 3.12 3.42 3.53 3.52 3.70 3.41 3.13
Altman Z-Score
2.97 2.81 3.17 3.33 3.25 3.16 3.03 3.09 3.06 3.23 3.09
Noncontrolling Interest Sharing Ratio
0.26% 0.26% 0.27% 0.26% 0.26% 0.25% 0.23% 0.22% 0.22% 0.21% 0.17%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.43 1.45 1.50 1.49 1.37 1.44 1.41 1.44 1.43 1.40 1.35
Quick Ratio
1.07 1.13 1.17 1.13 1.03 1.11 1.11 1.14 1.11 1.09 1.05
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-1,990 -5,528 -4,159 -5,782 -2,847 -412 1,726 3,331 3,477 1,663 3,034
Operating Cash Flow to CapEx
518.88% 219.25% 806.33% 138.39% 708.96% -911.35% 819.12% 557.14% 2,149.17% -509.40% 1,614.43%
Free Cash Flow to Firm to Interest Expense
-5.79 -16.26 -13.86 -20.65 -10.74 -1.59 6.66 12.76 13.85 7.26 14.24
Operating Cash Flow to Interest Expense
2.96 2.08 8.92 1.60 7.46 -11.47 10.09 7.47 25.77 -6.63 23.12
Operating Cash Flow Less CapEx to Interest Expense
2.39 1.13 7.82 0.44 6.41 -12.73 8.86 6.13 24.57 -7.93 21.69
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
1.58 1.57 1.53 1.55 1.55 1.62 1.58 1.58 1.53 1.56 1.52
Accounts Receivable Turnover
17.29 16.82 17.20 16.94 19.27 18.11 20.35 20.04 20.37 18.73 21.40
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
40.39 39.24 39.76 38.17 38.73 39.50 39.93 38.37 38.24 38.03 38.16
Accounts Payable Turnover
23.96 21.29 24.43 26.21 26.92 22.63 11.01 10.90 10.59 24.52 9.67
Days Sales Outstanding (DSO)
21.11 21.70 21.23 21.54 18.94 20.16 17.94 18.21 17.92 19.49 17.06
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
15.23 17.14 14.94 13.93 13.56 16.13 33.16 33.50 34.46 14.89 37.76
Cash Conversion Cycle (CCC)
5.88 4.56 6.29 7.62 5.38 4.03 -15.23 -15.28 -16.54 4.60 -20.71
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
27,744 27,346 22,970 26,498 23,301 21,173 17,554 18,384 18,002 19,715 17,776
Invested Capital Turnover
7.18 7.29 8.59 7.65 8.32 8.38 9.55 8.71 8.62 7.83 8.32
Increase / (Decrease) in Invested Capital
4,443 6,173 5,416 8,114 5,299 1,458 -222 -1,277 -1,281 -594 -1,276
Enterprise Value (EV)
84,130 71,434 99,613 110,080 104,529 91,195 80,479 84,176 88,438 102,823 89,155
Market Capitalization
98,889 85,556 120,581 125,938 121,836 109,328 101,348 103,997 107,792 119,351 107,370
Book Value per Share
$186.95 $178.14 $188.78 $181.53 $174.72 $167.29 $163.05 $161.16 $157.32 $151.75 $149.96
Tangible Book Value per Share
$9.43 $4.07 $32.27 $24.88 $17.00 $15.82 $11.21 $9.40 $4.92 $6.47 $4.48
Total Capital
72,623 72,658 71,027 69,983 67,161 64,525 63,383 63,436 62,926 60,444 59,815
Total Debt
30,003 31,232 27,148 27,686 26,451 25,120 24,844 25,124 25,466 24,114 23,772
Total Long-Term Debt
28,110 29,218 24,688 24,561 21,976 23,246 24,045 24,859 25,201 22,349 21,258
Net Debt
-14,876 -14,233 -21,072 -15,964 -17,409 -18,232 -20,985 -19,928 -19,458 -16,615 -18,267
Capital Expenditures (CapEx)
196 322 332 323 279 326 319 350 301 298 305
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-13,336 -14,306 -14,660 -12,405 -15,178 -16,257 -20,248 -19,847 -19,971 -16,606 -19,071
Debt-free Net Working Capital (DFNWC)
20,316 20,375 23,273 23,586 21,089 20,112 18,647 18,437 18,199 17,686 16,830
Net Working Capital (NWC)
18,423 18,361 20,813 20,461 16,614 18,238 17,848 18,172 17,934 15,921 14,316
Net Nonoperating Expense (NNE)
269 232 249 31 203 215 204 198 192 192 160
Net Nonoperating Obligations (NNO)
-14,876 -14,080 -20,909 -15,799 -17,409 -18,232 -20,985 -19,928 -19,458 -16,615 -18,267
Total Depreciation and Amortization (D&A)
373 398 329 335 331 424 426 433 462 473 451
Debt-free, Cash-free Net Working Capital to Revenue
-7.28% -8.09% -8.42% -7.22% -8.84% -9.49% -12.01% -11.98% -12.43% -10.60% -12.44%
Debt-free Net Working Capital to Revenue
11.09% 11.52% 13.37% 13.74% 12.28% 11.74% 11.06% 11.13% 11.33% 11.29% 10.98%
Net Working Capital to Revenue
10.06% 10.38% 11.96% 11.92% 9.67% 10.64% 10.58% 10.97% 11.16% 10.17% 9.34%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$9.64 $1.87 $4.38 $9.91 $9.65 $3.70 $5.48 $0.00 $8.37 $3.66 $6.75
Adjusted Weighted Average Basic Shares Outstanding
225.93M 227.35M 231.92M 231.89M 232.42M 232.67M 234.96M 0.00 237.06M 237.46M 238.83M
Adjusted Diluted Earnings per Share
$9.61 $1.88 $4.36 $9.85 $9.59 $3.68 $5.45 $0.00 $8.30 $3.61 $6.68
Adjusted Weighted Average Diluted Shares Outstanding
225.93M 227.35M 231.92M 231.89M 232.42M 232.67M 234.96M 0.00 237.06M 237.46M 238.83M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
225.93M 227.35M 231.92M 231.89M 232.42M 232.67M 234.96M 0.00 237.06M 237.46M 238.83M
Normalized Net Operating Profit after Tax (NOPAT)
2,453 645 1,257 2,332 2,452 1,046 1,504 2,054 2,196 1,069 1,758
Normalized NOPAT Margin
5.02% 1.42% 2.78% 5.34% 5.76% 2.45% 3.51% 4.70% 5.21% 2.68% 4.40%
Pre Tax Income Margin
5.72% 1.33% 3.04% 6.84% 6.90% 2.35% 3.86% 5.59% 6.21% 2.62% 5.33%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
9.13 2.78 5.58 11.66 12.09 4.86 7.39 10.35 11.43 5.56 10.99
NOPAT to Interest Expense
7.13 1.90 4.19 8.33 9.25 4.04 5.81 7.87 8.75 4.67 8.25
EBIT Less CapEx to Interest Expense
8.56 1.84 4.47 10.51 11.04 3.61 6.15 9.01 10.24 4.26 9.55
NOPAT Less CapEx to Interest Expense
6.56 0.95 3.08 7.17 8.20 2.78 4.57 6.53 7.55 3.37 6.82
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
25.65% 25.26% 23.18% 21.72% 22.82% 23.28% 22.43% 20.71% 20.79% 20.87% 19.51%
Augmented Payout Ratio
80.07% 73.82% 54.75% 58.19% 64.83% 67.95% 60.79% 58.83% 59.94% 60.21% 56.50%

Frequently Asked Questions About Elevance Health's Financials

When does Elevance Health's fiscal year end?

According to the most recent income statement we have on file, Elevance Health's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Elevance Health's net income changed over the last 9 years?

Elevance Health's net income appears to be on an upward trend, with a most recent value of $5.97 billion in 2024, rising from $2.56 billion in 2015. The previous period was $5.99 billion in 2023. See Elevance Health's forecast for analyst expectations on what’s next for the company.

What is Elevance Health's operating income?
Elevance Health's total operating income in 2024 was $8.89 billion, based on the following breakdown:
  • Total Gross Profit: $29.49 billion
  • Total Operating Expenses: $20.61 billion
How has Elevance Health revenue changed over the last 9 years?

Over the last 9 years, Elevance Health's total revenue changed from $79.16 billion in 2015 to $176.81 billion in 2024, a change of 123.4%.

How much debt does Elevance Health have?

Elevance Health's total liabilities were at $75.46 billion at the end of 2024, a 8.5% increase from 2023, and a 95.1% increase since 2015.

How much cash does Elevance Health have?

In the past 9 years, Elevance Health's cash and equivalents has ranged from $2.11 billion in 2015 to $8.29 billion in 2024, and is currently $8.29 billion as of their latest financial filing in 2024.

How has Elevance Health's book value per share changed over the last 9 years?

Over the last 9 years, Elevance Health's book value per share changed from 88.27 in 2015 to 178.14 in 2024, a change of 101.8%.



This page (NYSE:ELV) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners